Details of the Drug

General Information of Drug (ID: DM6HX9B)

Drug Name
Nevirapine
Synonyms
NEV; NVP; Viramune; Cahill May Roberts Brand of Nevirapine; Promeco Brand of Nevirapine; BI RG 587; BIRG 0587; BIRG 587; BIRG587; BIRG-0587; BIRG-587; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; Nevirapine & PRO 140; Nevirapine [USAN:INN]; Viramune (TN); Viramune(TM); BI-RG-587; Nevirapine & CD4-IgG; Nevirapine (JAN/USP/INN); Viramune, BI-RG 587, Nevirapine; BI-RG-587 & CD4-IgG; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1]
Therapeutic Class
Anti-HIV Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 266.3
Topological Polar Surface Area (xlogp) 2
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Bioavailability
93% of drug becomes completely available to its intended biological destination(s) [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.3 mL/min/kg [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 45 hours [4]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 21.4573 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.32% [4]
Vd
The volume of distribution (Vd) of drug is 1.21 +/- 0.09 L/kg [7]
Water Solubility
The ability of drug to dissolve in water is measured as 0.1 mg/mL [2]
Chemical Identifiers
Formula
C15H14N4O
IUPAC Name
2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one
Canonical SMILES
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
InChI
InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)
InChIKey
NQDJXKOVJZTUJA-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4463
ChEBI ID
CHEBI:63613
CAS Number
129618-40-2
DrugBank ID
DB00238
TTD ID
D0O2EM
VARIDT ID
DR00447
INTEDE ID
DR1142
ACDINA ID
D00464

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Modulator [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [11]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [12]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [13]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Nevirapine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
MK-1439 DM215WE Major Increased metabolism of Nevirapine caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [78]
Delavirdine DM3NF5G Moderate Decreased metabolism of Nevirapine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [79]
Fosamprenavir DM4W9B3 Moderate Increased metabolism of Nevirapine caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [80]
Fostemsavir DM50ILT Minor Increased metabolism of Nevirapine caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [81]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Nevirapine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [82]
Tipranavir DM8HJX6 Moderate Increased metabolism of Nevirapine caused by Tipranavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [82]
Dolutegravir DMCZGRE Major Increased metabolism of Nevirapine caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Saquinavir DMG814N Moderate Increased metabolism of Nevirapine caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [80]
Elvitegravir DMG9B1U Moderate Increased metabolism of Nevirapine caused by Elvitegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [82]
Etravirine DMGV8QU Major Increased metabolism of Nevirapine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [84]
Lopinavir DMITQS0 Major Increased metabolism of Nevirapine caused by Lopinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Amprenavir DMLMXE0 Moderate Increased metabolism of Nevirapine caused by Amprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [80]
Darunavir DMN3GCH Moderate Increased metabolism of Nevirapine caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [82]
Atazanavir DMSYRBX Major Decreased metabolism of Nevirapine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [82]
Raltegravir DMYURI6 Minor Increased metabolism of Nevirapine caused by Raltegravir mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [86]
⏷ Show the Full List of 15 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Nevirapine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Nevirapine and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [82]
Methylergonovine DMBEX4O Moderate Increased metabolism of Nevirapine caused by Methylergonovine mediated induction of CYP450 enzyme. Abortion [JA00] [82]
Tretinoin DM49DUI Moderate Increased metabolism of Nevirapine caused by Tretinoin mediated induction of CYP450 enzyme. Acne vulgaris [ED80] [82]
Isotretinoin DM4QTBN Moderate Increased metabolism of Nevirapine caused by Isotretinoin mediated induction of CYP450 enzyme. Acne vulgaris [ED80] [82]
Repaglinide DM5SXUV Moderate Increased metabolism of Nevirapine caused by Repaglinide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [87]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Nevirapine and Thioguanine. Acute myeloid leukaemia [2A60] [88]
Midostaurin DMI6E0R Moderate Increased metabolism of Nevirapine caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [89]
Gilteritinib DMWQ4MZ Moderate Increased metabolism of Nevirapine caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [90]
Oliceridine DM6MDCF Major Increased metabolism of Nevirapine caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [86]
Terfenadine DM4KLPT Moderate Increased metabolism of Nevirapine caused by Terfenadine mediated induction of CYP450 enzyme. Allergic/hypersensitivity disorder [4A80-4A8Z] [82]
Loratadine DMF3AN7 Moderate Increased metabolism of Nevirapine caused by Loratadine mediated induction of CYP450 enzyme. Allergic/hypersensitivity disorder [4A80-4A8Z] [82]
Donepezil DMIYG7Z Moderate Increased metabolism of Nevirapine caused by Donepezil mediated induction of CYP450 enzyme. Alzheimer disease [8A20] [91]
Ranolazine DM0C9IL Major Increased metabolism of Nevirapine caused by Ranolazine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [92]
Ivabradine DM0L594 Moderate Increased metabolism of Nevirapine caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [93]
Bepridil DM0RKS4 Moderate Increased metabolism of Nevirapine caused by Bepridil mediated induction of CYP450 enzyme. Angina pectoris [BA40] [82]
Dronedarone DMA8FS5 Moderate Increased metabolism of Nevirapine caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [94]
Nifedipine DMSVOZT Moderate Increased metabolism of Nevirapine caused by Nifedipine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [82]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Nevirapine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [95]
Buspirone DMBS632 Moderate Increased metabolism of Nevirapine caused by Buspirone mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [96]
Clorazepate DMC3JST Moderate Increased metabolism of Nevirapine caused by Clorazepate mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [93]
Alprazolam DMC7XDN Moderate Increased metabolism of Nevirapine caused by Alprazolam mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [82]
Voriconazole DMAOL2S Moderate Increased metabolism of Nevirapine caused by Voriconazole mediated induction of CYP450 enzyme. Aspergillosis [1F20] [97]
Posaconazole DMUL5EW Moderate Decreased metabolism of Nevirapine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [93]
Montelukast DMD157S Moderate Increased metabolism of Nevirapine caused by Montelukast mediated induction of CYP450 enzyme. Asthma [CA23] [98]
Budesonide DMJIBAW Moderate Increased metabolism of Nevirapine caused by Budesonide mediated induction of CYP450 enzyme. Asthma [CA23] [82]
Zileuton DMVRIC2 Moderate Increased metabolism of Nevirapine caused by Zileuton mediated induction of CYP450 enzyme. Asthma [CA23] [82]
Tindamax DM3OWT4 Moderate Increased metabolism of Nevirapine caused by Tindamax mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [82]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Nevirapine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [99]
Clarithromycin DM4M1SG Moderate Increased metabolism of Nevirapine caused by Clarithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [85]
Rabeprazole DMMZXIW Moderate Increased metabolism of Nevirapine caused by Rabeprazole mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [82]
Troleandomycin DMUZNIG Moderate Increased metabolism of Nevirapine caused by Troleandomycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [82]
Telithromycin DMZ4P3A Moderate Increased metabolism of Nevirapine caused by Telithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [100]
Cariprazine DMJYDVK Moderate Increased metabolism of Nevirapine caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [101]
Erdafitinib DMI782S Major Increased metabolism of Nevirapine caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [102]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Nevirapine and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [103]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Nevirapine caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [104]
Lapatinib DM3BH1Y Moderate Increased metabolism of Nevirapine caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [82]
HKI-272 DM6QOVN Major Increased metabolism of Nevirapine caused by HKI-272 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [82]
LY2835219 DM93VBZ Moderate Increased metabolism of Nevirapine caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [105]
Exemestane DM9HPW3 Moderate Increased metabolism of Nevirapine caused by Exemestane mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [106]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Nevirapine caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [107]
Tucatinib DMBESUA Moderate Increased metabolism of Nevirapine caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [108]
Palbociclib DMD7L94 Moderate Increased metabolism of Nevirapine caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [82]
Alpelisib DMEXMYK Moderate Increased metabolism of Nevirapine caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [109]
Letrozole DMH07Y3 Moderate Increased metabolism of Nevirapine caused by Letrozole mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [82]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Nevirapine caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [107]
Tamoxifen DMLB0EZ Moderate Increased metabolism of Nevirapine caused by Tamoxifen mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [110]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Nevirapine caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [111]
Toremifene DMQYUWG Moderate Increased metabolism of Nevirapine caused by Toremifene mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [112]
Bosutinib DMTI8YE Moderate Increased metabolism of Nevirapine caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [113]
Estradiol DMUNTE3 Moderate Increased metabolism of Nevirapine caused by Estradiol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [107]
Atorvastatin DMF28YC Moderate Increased metabolism of Nevirapine caused by Atorvastatin mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [114]
Macitentan DMP79A1 Moderate Increased metabolism of Nevirapine caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [115]
Doxercalciferol DM6FG1P Moderate Increased metabolism of Nevirapine caused by Doxercalciferol mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [82]
PF-04449913 DMSB068 Major Increased metabolism of Nevirapine caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [116]
Vilanterol DMF5EK1 Moderate Increased metabolism of Nevirapine caused by Vilanterol mediated induction of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [93]
Indacaterol DMQJHR7 Moderate Increased metabolism of Nevirapine caused by Indacaterol mediated induction of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [82]
Dihydrocodeine DMB0FWL Moderate Increased metabolism of Nevirapine caused by Dihydrocodeine mediated induction of CYP450 enzyme. Chronic pain [MG30] [117]
Irinotecan DMP6SC2 Moderate Increased metabolism of Nevirapine caused by Irinotecan mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [118]
Intedanib DMSTA36 Moderate Increased metabolism of Nevirapine caused by Intedanib mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [82]
Drospirenone DM1A9W3 Moderate Increased metabolism of Nevirapine caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [85]
Levonorgestrel DM1DP7T Moderate Increased metabolism of Nevirapine caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [85]
Desogestrel DM27U4Y Moderate Increased metabolism of Nevirapine caused by Desogestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [85]
Ulipristal DMBNI20 Moderate Increased metabolism of Nevirapine caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [93]
Mestranol DMG3F94 Moderate Increased metabolism of Nevirapine caused by Mestranol mediated induction of CYP450 enzyme. Contraceptive management [QA21] [85]
Etonogestrel DMKA8J4 Moderate Increased metabolism of Nevirapine caused by Etonogestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [85]
Levobupivacaine DM783CH Minor Increased metabolism of Nevirapine caused by Levobupivacaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [119]
Halothane DM80OZ5 Moderate Increased metabolism of Nevirapine caused by Halothane mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [82]
Lidocaine DML4ZOT Minor Increased metabolism of Nevirapine caused by Lidocaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [120]
Ropivacaine DMSPJG2 Moderate Increased metabolism of Nevirapine caused by Ropivacaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [82]
Alfentanil DMVO0UB Moderate Increased metabolism of Nevirapine caused by Alfentanil mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [121]
Nimodipine DMQ0RKZ Moderate Increased metabolism of Nevirapine caused by Nimodipine mediated induction of CYP450 enzyme. Coronary vasospastic disease [BA85] [82]
Methadone DMTW6IU Moderate Increased metabolism of Nevirapine caused by Methadone mediated induction of CYP450 enzyme. Cough [MD12] [122]
Mifepristone DMGZQEF Moderate Increased metabolism of Nevirapine caused by Mifepristone mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [123]
Osilodrostat DMIJC9X Moderate Increased metabolism of Nevirapine caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [124]
Ivacaftor DMZC1HS Moderate Increased metabolism of Nevirapine caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [125]
MK-8228 DMOB58Q Moderate Decreased metabolism of Nevirapine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [82]
Rivaroxaban DMQMBZ1 Moderate Increased metabolism of Nevirapine caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [126]
Aprepitant DM053KT Moderate Increased metabolism of Nevirapine caused by Aprepitant mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [127]
Cyclobenzaprine DM1YBRM Moderate Increased metabolism of Nevirapine caused by Cyclobenzaprine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [82]
Vilazodone DM4LECQ Moderate Increased metabolism of Nevirapine caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [128]
Vortioxetine DM6F1PU Moderate Increased metabolism of Nevirapine caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [129]
Trazodone DMK1GBJ Moderate Increased metabolism of Nevirapine caused by Trazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [82]
Mirtazapine DML53ZJ Moderate Increased metabolism of Nevirapine caused by Mirtazapine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [130]
Venlafaxine DMR6QH0 Moderate Increased metabolism of Nevirapine caused by Venlafaxine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [82]
Oxybutynine DMJPBAX Moderate Increased metabolism of Nevirapine caused by Oxybutynine mediated induction of CYP450 enzyme. Discovery agent [N.A.] [82]
Ingrezza DMVPLNC Moderate Increased metabolism of Nevirapine caused by Ingrezza mediated induction of CYP450 enzyme. Dystonic disorder [8A02] [82]
Zonisamide DM0DTF7 Moderate Increased metabolism of Nevirapine caused by Zonisamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [131]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Nevirapine caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [132]
Ethosuximide DMDZ9LT Moderate Increased metabolism of Nevirapine caused by Ethosuximide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [82]
Cenobamate DMGOVHA Moderate Increased metabolism of Nevirapine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [133]
Tiagabine DMKSQG0 Moderate Increased metabolism of Nevirapine caused by Tiagabine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [82]
Stiripentol DMMSDOY Moderate Increased metabolism of Nevirapine caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [93]
Phenytoin DMNOKBV Moderate Increased metabolism of Nevirapine caused by Phenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [134]
Clonazepam DMTO13J Moderate Increased metabolism of Nevirapine caused by Clonazepam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [82]
Carbamazepine DMZOLBI Moderate Increased metabolism of Nevirapine caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [134]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Nevirapine and Cannabidiol. Epileptic encephalopathy [8A62] [93]
Nicardipine DMCDYW7 Moderate Increased metabolism of Nevirapine caused by Nicardipine mediated induction of CYP450 enzyme. Essential hypertension [BA00] [82]
Praziquantel DMOU1PK Moderate Increased metabolism of Nevirapine caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [135]
Bay 80-6946 DMLOS5R Moderate Increased metabolism of Nevirapine caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [136]
Tazemetostat DMWP1BH Major Increased metabolism of Nevirapine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [137]
Solifenacin DMG592Q Moderate Increased metabolism of Nevirapine caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [138]
Mirabegron DMS1GYT Minor Increased metabolism of Nevirapine caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [139]
Tolterodine DMSHPW8 Moderate Increased metabolism of Nevirapine caused by Tolterodine mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [82]
Darifenacin DMWXLYZ Moderate Increased metabolism of Nevirapine caused by Darifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [140]
Itraconazole DMCR1MV Moderate Decreased metabolism of Nevirapine caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [141]
Caspofungin DMGQIPT Major Increased metabolism of Nevirapine caused by Caspofungin mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [142]
Cisapride DMY7PED Moderate Increased metabolism of Nevirapine caused by Cisapride mediated induction of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [82]
Ripretinib DM958QB Moderate Increased metabolism of Nevirapine caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [82]
Sunitinib DMCBJSR Moderate Increased metabolism of Nevirapine caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [82]
Avapritinib DMK2GZX Major Increased metabolism of Nevirapine caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [93]
Ergotamine DMKR3C5 Moderate Increased metabolism of Nevirapine caused by Ergotamine mediated induction of CYP450 enzyme. Headache [8A80-8A84] [82]
Eplerenone DMF0NQR Moderate Increased metabolism of Nevirapine caused by Eplerenone mediated induction of CYP450 enzyme. Heart failure [BD10-BD1Z] [82]
Boceprevir DMBSHMF Moderate Increased metabolism of Nevirapine caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [143]
ABT-450 DMFW860 Major Increased metabolism of Nevirapine caused by ABT-450 mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [82]
Simeprevir DMLUA9D Major Increased metabolism of Nevirapine caused by Simeprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [144]
Telaprevir DMMRV29 Moderate Increased metabolism of Nevirapine caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [143]
Daclatasvir DMSFK9V Major Increased metabolism of Nevirapine caused by Daclatasvir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [82]
Rifampin DMA8J1G Major Increased metabolism of Nevirapine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [93]
Rifapentine DMCHV4I Moderate Increased metabolism of Nevirapine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [145]
Pretomanid DMDYA31 Major Increased metabolism of Nevirapine caused by Pretomanid mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [146]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Nevirapine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [147]
Simvastatin DM30SGU Moderate Increased metabolism of Nevirapine caused by Simvastatin mediated induction of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [114]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Nevirapine and Mipomersen. Hyper-lipoproteinaemia [5C80] [148]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Nevirapine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [86]
Cerivastatin DMXCM7H Moderate Increased metabolism of Nevirapine caused by Cerivastatin mediated induction of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [114]
Paricalcitol DMYBV3G Moderate Increased metabolism of Nevirapine caused by Paricalcitol mediated induction of CYP450 enzyme. Hyper-parathyroidism [5A51] [82]
Levamlodipine DM92S6N Moderate Increased metabolism of Nevirapine caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [82]
Doxazosin DM9PLRH Moderate Increased metabolism of Nevirapine caused by Doxazosin mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [82]
Isradipine DMA5XGH Moderate Increased metabolism of Nevirapine caused by Isradipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [82]
Verapamil DMA7PEW Moderate Increased metabolism of Nevirapine caused by Verapamil mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [82]
Diltiazem DMAI7ZV Moderate Increased metabolism of Nevirapine caused by Diltiazem mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [149]
Amlodipine DMBDAZV Moderate Increased metabolism of Nevirapine caused by Amlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [82]
Felodipine DMOSW35 Moderate Increased metabolism of Nevirapine caused by Felodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [82]
Conivaptan DM1V329 Moderate Decreased metabolism of Nevirapine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [150]
Tolvaptan DMIWFRL Moderate Increased metabolism of Nevirapine caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [93]
Fludrocortisone DMUDIR8 Moderate Increased metabolism of Nevirapine caused by Fludrocortisone mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [82]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Nevirapine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [151]
Suvorexant DM0E6S3 Moderate Increased metabolism of Nevirapine caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [152]
Ramelteon DM7IW9J Moderate Increased metabolism of Nevirapine caused by Ramelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [153]
Eszopiclone DM8RZ9H Moderate Increased metabolism of Nevirapine caused by Eszopiclone mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [154]
Flurazepam DMAL4G0 Moderate Increased metabolism of Nevirapine caused by Flurazepam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [82]
Triazolam DMETYK5 Moderate Increased metabolism of Nevirapine caused by Triazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [82]
ITI-007 DMUQ1DO Major Increased metabolism of Nevirapine caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [155]
Zolpidem DMWOSKJ Moderate Increased metabolism of Nevirapine caused by Zolpidem mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [93]
Estazolam DMZGXUM Moderate Increased metabolism of Nevirapine caused by Estazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [82]
Naloxegol DML0B41 Moderate Increased metabolism of Nevirapine caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [156]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Nevirapine and Methotrexate. Leukaemia [2A60-2B33] [93]
Pemigatinib DM819JF Major Increased metabolism of Nevirapine caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [93]
Testosterone DM7HUNW Moderate Increased metabolism of Nevirapine caused by Testosterone mediated induction of CYP450 enzyme. Low bone mass disorder [FB83] [82]
Crizotinib DM4F29C Moderate Increased metabolism of Nevirapine caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [157]
Brigatinib DM7W94S Major Increased metabolism of Nevirapine caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [82]
Ceritinib DMB920Z Moderate Increased metabolism of Nevirapine caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [158]
Erlotinib DMCMBHA Moderate Increased metabolism of Nevirapine caused by Erlotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [159]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Nevirapine caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [160]
PF-06463922 DMKM7EW Major Increased metabolism of Nevirapine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [161]
Osimertinib DMRJLAT Moderate Increased metabolism of Nevirapine caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [162]
Pralsetinib DMWU0I2 Moderate Increased metabolism of Nevirapine caused by Pralsetinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [163]
Capmatinib DMYCXKL Major Increased metabolism of Nevirapine caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [164]
Selpercatinib DMZR15V Major Increased metabolism of Nevirapine caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [93]
Artemether DM48QOT Major Increased metabolism of Nevirapine caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [82]
Halofantrine DMOMK1V Moderate Increased metabolism of Nevirapine caused by Halofantrine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [82]
Quinine DMSWYF5 Moderate Increased metabolism of Nevirapine caused by Quinine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [165]
Mefloquine DMWT905 Moderate Increased metabolism of Nevirapine caused by Mefloquine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [166]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Nevirapine and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [167]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Nevirapine and Idelalisib. Mature B-cell leukaemia [2A82] [168]
GDC-0199 DMH0QKA Major Increased metabolism of Nevirapine caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [169]
IPI-145 DMWA24P Moderate Increased metabolism of Nevirapine caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [170]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Nevirapine caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [171]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Nevirapine and Clofarabine. Mature B-cell lymphoma [2A85] [172]
Ibrutinib DMHZCPO Moderate Increased metabolism of Nevirapine caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [173]
Vincristine DMINOX3 Moderate Increased metabolism of Nevirapine caused by Vincristine mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [174]
Teniposide DMLW57T Moderate Increased metabolism of Nevirapine caused by Teniposide mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [82]
Ponatinib DMYGJQO Moderate Increased metabolism of Nevirapine caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [82]
Vemurafenib DM62UG5 Moderate Increased metabolism of Nevirapine caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [175]
Selumetinib DMC7W6R Major Increased metabolism of Nevirapine caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [176]
LGX818 DMNQXV8 Moderate Increased metabolism of Nevirapine caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [177]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Nevirapine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [93]
Estrone DM5T6US Moderate Increased metabolism of Nevirapine caused by Estrone mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [107]
Conjugated estrogens DMLT0E1 Moderate Increased metabolism of Nevirapine caused by Conjugated estrogens mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [107]
Ethinyl estradiol DMODJ40 Moderate Increased metabolism of Nevirapine caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [85]
Nitisinone DMVS9WQ Moderate Increased metabolism of Nevirapine caused by Nitisinone mediated induction of CYP450 enzyme. Metabolism inborn error [5C50] [86]
Methysergide DM1EF73 Moderate Increased metabolism of Nevirapine caused by Methysergide mediated induction of CYP450 enzyme. Migraine [8A80] [82]
Ubrogepant DM749I3 Moderate Increased metabolism of Nevirapine caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [178]
Rimegepant DMHOAUG Major Increased metabolism of Nevirapine caused by Rimegepant mediated induction of CYP450 enzyme. Migraine [8A80] [179]
Exjade DMHPRWG Moderate Decreased metabolism of Nevirapine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [180]
Flibanserin DM70DTN Moderate Increased metabolism of Nevirapine caused by Flibanserin mediated induction of CYP450 enzyme. Mood disorder [6A60-6E23] [181]
Midazolam DMXOELT Moderate Increased metabolism of Nevirapine caused by Midazolam mediated induction of CYP450 enzyme. Mood/affect symptom [MB24] [82]
Panobinostat DM58WKG Moderate Increased metabolism of Nevirapine caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [182]
Siponimod DM2R86O Major Increased metabolism of Nevirapine caused by Siponimod mediated induction of CYP450 enzyme. Multiple sclerosis [8A40] [82]
Deflazacort DMV0RNS Major Increased metabolism of Nevirapine caused by Deflazacort mediated induction of CYP450 enzyme. Muscular dystrophy [8C70] [93]
Rifabutin DM1YBHK Minor Increased metabolism of Nevirapine caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [85]
Bexarotene DMOBIKY Minor Increased metabolism of Nevirapine caused by Bexarotene mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [183]
Romidepsin DMT5GNL Moderate Increased metabolism of Nevirapine caused by Romidepsin mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [82]
Fedratinib DM4ZBK6 Moderate Increased metabolism of Nevirapine caused by Fedratinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [82]
Nilotinib DM7HXWT Moderate Increased metabolism of Nevirapine caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [184]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Nevirapine caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [185]
Imatinib DM7RJXL Moderate Increased metabolism of Nevirapine caused by Imatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [186]
Prasugrel DM7MT6E Minor Decreased metabolism of Nevirapine caused by Prasugrel mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [93]
Vorapaxar DMA16BR Moderate Increased metabolism of Nevirapine caused by Vorapaxar mediated induction of CYP450 enzyme. Myocardial infarction [BA41-BA43] [82]
Modafinil DMYILBE Moderate Increased metabolism of Nevirapine caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [187]
Rolapitant DM8XP26 Moderate Increased metabolism of Nevirapine caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [93]
Granisetron DMIUW25 Moderate Increased metabolism of Nevirapine caused by Granisetron mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [82]
Ondansetron DMOTQ1I Moderate Increased metabolism of Nevirapine caused by Ondansetron mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [82]
E-2007 DMJDYNQ Moderate Increased metabolism of Nevirapine caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [93]
Bupropion DM5PCS7 Moderate Increased metabolism of Nevirapine caused by Bupropion mediated induction of CYP450 enzyme. Nicotine use disorder [6C4A] [82]
Entrectinib DMMPTLH Major Increased metabolism of Nevirapine caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [188]
Sibutramine DMFJTDI Moderate Increased metabolism of Nevirapine caused by Sibutramine mediated induction of CYP450 enzyme. Obesity [5B80-5B81] [82]
Orlistat DMRJSP8 Moderate Altered absorption of Nevirapine caused by Orlistat. Obesity [5B80-5B81] [189]
S-297995 DM26IH8 Moderate Increased metabolism of Nevirapine caused by S-297995 mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [82]
Valdecoxib DMAY7H4 Moderate Increased metabolism of Nevirapine caused by Valdecoxib mediated induction of CYP450 enzyme. Osteoarthritis [FA00-FA05] [82]
Olaparib DM8QB1D Major Increased metabolism of Nevirapine caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [82]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Nevirapine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [190]
Codeine DMJX6ZG Moderate Increased metabolism of Nevirapine caused by Codeine mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [117]
Buprenorphine DMPRI8G Moderate Increased metabolism of Nevirapine caused by Buprenorphine mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [191]
Hydrocodone DMQ2JO5 Major Increased metabolism of Nevirapine caused by Hydrocodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [86]
Oxycodone DMXLKHV Major Increased metabolism of Nevirapine caused by Oxycodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [86]
Albendazole DMYZ57N Moderate Increased metabolism of Nevirapine caused by Albendazole mediated induction of CYP450 enzyme. Parasitic worm infestation [1F90] [82]
Istradefylline DM20VSK Moderate Increased metabolism of Nevirapine caused by Istradefylline mediated induction of CYP450 enzyme. Parkinsonism [8A00] [192]
Pimavanserin DMR7IVC Moderate Increased metabolism of Nevirapine caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [193]
Abametapir DM2RX0I Moderate Decreased metabolism of Nevirapine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [194]
Macimorelin DMQYJIR Moderate Increased metabolism of Nevirapine caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [195]
Dapsone DM4LT8A Minor Increased metabolism of Nevirapine caused by Dapsone mediated induction of CYP450 enzyme. Pneumonia [CA40] [196]
Prednisone DM2HG4X Moderate Increased metabolism of Nevirapine caused by Prednisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [82]
Betamethasone DMAHJEF Moderate Increased metabolism of Nevirapine caused by Betamethasone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [82]
Ergonovine DM0VEC1 Moderate Increased metabolism of Nevirapine caused by Ergonovine mediated induction of CYP450 enzyme. Postpartum haemorrhage [JA43] [82]
Lonafarnib DMGM2Z6 Major Increased metabolism of Nevirapine caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [197]
Progesterone DMUY35B Moderate Increased metabolism of Nevirapine caused by Progesterone mediated induction of CYP450 enzyme. Preterm labour/delivery [JB00] [107]
ABIRATERONE DM8V75C Moderate Increased metabolism of Nevirapine caused by ABIRATERONE mediated induction of CYP450 enzyme. Prostate cancer [2C82] [82]
Enzalutamide DMGL19D Moderate Increased metabolism of Nevirapine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [198]
Darolutamide DMV7YFT Moderate Increased metabolism of Nevirapine caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [199]
Tamsulosin DM5QF9V Moderate Increased metabolism of Nevirapine caused by Tamsulosin mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [82]
Silodosin DMJSBT6 Moderate Increased metabolism of Nevirapine caused by Silodosin mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [82]
Dutasteride DMQ4TJK Moderate Increased metabolism of Nevirapine caused by Dutasteride mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [82]
Apremilast DMTWS9E Moderate Increased metabolism of Nevirapine caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [200]
Bosentan DMIOGBU Moderate Increased metabolism of Nevirapine caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [82]
Riociguat DMXBLMP Moderate Increased metabolism of Nevirapine caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [201]
Everolimus DM8X2EH Moderate Increased metabolism of Nevirapine caused by Everolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [82]
Temsirolimus DMS104F Moderate Increased metabolism of Nevirapine caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [82]
Sorafenib DMS8IFC Moderate Increased metabolism of Nevirapine caused by Sorafenib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [202]
Upadacitinib DM32B5U Moderate Increased metabolism of Nevirapine caused by Upadacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [203]
Tofacitinib DMBS370 Moderate Increased metabolism of Nevirapine caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [82]
Dexamethasone DMMWZET Moderate Increased metabolism of Nevirapine caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [82]
Quetiapine DM1N62C Moderate Increased metabolism of Nevirapine caused by Quetiapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [82]
Aripiprazole DM3NUMH Moderate Increased metabolism of Nevirapine caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [204]
Haloperidol DM96SE0 Moderate Increased metabolism of Nevirapine caused by Haloperidol mediated induction of CYP450 enzyme. Schizophrenia [6A20] [82]
Ziprasidone DMM58JY Minor Increased metabolism of Nevirapine caused by Ziprasidone mediated induction of CYP450 enzyme. Schizophrenia [6A20] [205]
Asenapine DMSQZE2 Moderate Increased metabolism of Nevirapine caused by Asenapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [82]
Fentanyl DM8WAHT Major Increased metabolism of Nevirapine caused by Fentanyl mediated induction of CYP450 enzyme. Sensation disturbance [MB40] [86]
Avanafil DM75CXN Moderate Increased metabolism of Nevirapine caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [206]
Tadalafil DMJZHT1 Moderate Increased metabolism of Nevirapine caused by Tadalafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [93]
Voxelotor DMCS6M5 Major Increased metabolism of Nevirapine caused by Voxelotor mediated induction of CYP450 enzyme. Sickle-cell disorder [3A51] [207]
LDE225 DMM9F25 Major Increased metabolism of Nevirapine caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [208]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Nevirapine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [93]
Gefitinib DM15F0X Moderate Increased metabolism of Nevirapine caused by Gefitinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [159]
Larotrectinib DM26CQR Moderate Increased metabolism of Nevirapine caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [82]
Methylprednisolone DM4BDON Moderate Increased metabolism of Nevirapine caused by Methylprednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [82]
Cyclophosphamide DM4O2Z7 Moderate Increased metabolism of Nevirapine caused by Cyclophosphamide mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [82]
Vinblastine DM5TVS3 Moderate Increased metabolism of Nevirapine caused by Vinblastine mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [174]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Nevirapine and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [93]
Armodafinil DMGB035 Moderate Increased metabolism of Nevirapine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [187]
LEE011 DMMX75K Moderate Increased metabolism of Nevirapine caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [82]
Etoposide DMNH3PG Moderate Increased metabolism of Nevirapine caused by Etoposide mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [82]
Epirubicin DMPDW6T Moderate Increased risk of hepatotoxicity by the combination of Nevirapine and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [82]
Prednisolone DMQ8FR2 Moderate Increased metabolism of Nevirapine caused by Prednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [82]
Vandetanib DMRICNP Moderate Increased metabolism of Nevirapine caused by Vandetanib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [82]
Norethindrone DMTY169 Moderate Increased metabolism of Nevirapine caused by Norethindrone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [85]
Taxol DMUOT9V Moderate Increased metabolism of Nevirapine caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [209]
Doxorubicin DMVP5YE Moderate Increased metabolism of Nevirapine caused by Doxorubicin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [93]
Vinorelbine DMVXFYE Moderate Increased metabolism of Nevirapine caused by Vinorelbine mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [174]
Pitolisant DM8RFNJ Moderate Increased metabolism of Nevirapine caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [93]
Ivermectin DMDBX5F Moderate Increased metabolism of Nevirapine caused by Ivermectin mediated induction of CYP450 enzyme. Strongyloidiasis [1F6B] [82]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Nevirapine and Naltrexone. Substance abuse [6C40] [210]
Pomalidomide DMTGBAX Moderate Increased metabolism of Nevirapine caused by Pomalidomide mediated induction of CYP450 enzyme. Systemic sclerosis [4A42] [82]
Apixaban DM89JLN Moderate Increased metabolism of Nevirapine caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [211]
Brilinta DMBR01X Moderate Increased metabolism of Nevirapine caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [86]
Cabozantinib DMIYDT4 Moderate Decreased clearance of Nevirapine due to the transporter inhibition by Cabozantinib. Thyroid cancer [2D10] [82]
Sirolimus DMGW1ID Moderate Increased metabolism of Nevirapine caused by Sirolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [82]
Tacrolimus DMZ7XNQ Moderate Increased metabolism of Nevirapine caused by Tacrolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [82]
Saxagliptin DMGXENV Moderate Increased metabolism of Nevirapine caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [212]
Linagliptin DMWFJTR Moderate Increased metabolism of Nevirapine caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [213]
Elagolix DMB2C0E Moderate Increased metabolism of Nevirapine caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [214]
Astemizole DM2HN6Q Moderate Increased metabolism of Nevirapine caused by Astemizole mediated induction of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [82]
Triamcinolone DM98IXF Moderate Increased metabolism of Nevirapine caused by Triamcinolone mediated induction of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [82]
Fluticasone DMGCSVF Moderate Increased metabolism of Nevirapine caused by Fluticasone mediated induction of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [82]
Disopyramide DM5SYZP Moderate Increased metabolism of Nevirapine caused by Disopyramide mediated induction of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [82]
Amiodarone DMUTEX3 Major Increased metabolism of Nevirapine caused by Amiodarone mediated induction of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [215]
⏷ Show the Full List of 287 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium stearyl fumarate E00545 23665634 lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
Zinc stearate E00209 11178 lubricant
⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Nevirapine 100 mg tablet 100 mg 24 HR Extended Release Oral Tablet Oral
Nevirapine 200 mg tablet 200 mg Oral Tablet Oral
Nevirapine 400 mg tablet 400 mg 24 HR Extended Release Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Approved antiretroviral drugs. Antiretroviral Drugs. Company report of AVERT. 2009.
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
9 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
10 Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999 Dec;27(12):1488-95.
11 Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001 Jan;41(1):85-91.
12 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
13 RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):423-31.
14 Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92.
15 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
16 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
17 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
18 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
19 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
20 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
21 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
22 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
23 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
24 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
25 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
26 Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
27 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
28 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
29 CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
30 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
31 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
32 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
33 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
34 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
35 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
36 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
37 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
38 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
39 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
40 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
41 Drug Interactions Flockhart Table
42 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
43 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
44 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
45 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
46 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
47 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
48 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
49 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
50 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
51 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
52 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
53 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
54 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
55 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
56 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
57 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
58 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
59 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
60 Drugs that may have potential CYP2B6 interactions.
61 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
62 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
63 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
64 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
65 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
66 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
67 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
68 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
69 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
70 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
71 Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
72 A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
73 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
74 Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
75 Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
76 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
77 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
78 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
79 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
80 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
81 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
82 Cerner Multum, Inc. "Australian Product Information.".
83 Product Information. Dovato (dolutegravir-lamivudine). ViiV Healthcare, Research Triangle Park, NC.
84 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
85 Back D, Gibbons S, Khoo S "Pharmacokinetic drug interactions with nevirapine." J Acquir Immune Defic Syndr 34 Suppl 1 (2003): S8-14. [PMID: 14562853]
86 Canadian Pharmacists Association.
87 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
88 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
89 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
90 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
91 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
92 Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.
93 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
94 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
95 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
96 Kivisto KT, Lamberg TS, Neuvonen PJ "Interactions of buspirone with itraconazole and rifampicin: Effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone." Pharmacol Toxicol 84 (1999): 94-7. [PMID: 10068153]
97 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
98 Product Information. Singulair (montelukast). Merck & Co, Inc, West Point, PA.
99 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
100 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
101 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
102 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
103 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
104 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
105 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
106 Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
107 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
108 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
109 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
110 Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
111 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
112 Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes." Biochem Pharmacol 47 (1994): 1883-95. [PMID: 8204106]
113 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
114 Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. "Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study." J Acquir Immune Defic Syndr 39 (2005): 307-12. [PMID: 15980690]
115 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
116 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
117 Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514]
118 Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
119 Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
120 Heinonen J, Takki S, Jarho L "Plasma lidocaine levels in patients treated with potential inducers of microsomal enzymes." Acta Anaesthesiol Scand 14 (1970): 89-95. [PMID: 5428253]
121 Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
122 Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
123 He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
124 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
125 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
126 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
127 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
128 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
129 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
130 Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
131 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
132 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
133 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
134 L'homme RF, Dijkema T, van der Ven AJ, Burger DM "Enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women." J Acquir Immune Defic Syndr 43 (2006): 193-6. [PMID: 16940857]
135 Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
136 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
137 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
138 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
139 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
140 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
141 Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
142 Product Information. Cancidas (caspofungin) Merck & Co, Inc, West Point, PA.
143 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
144 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
145 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
146 Product Information. Pretomanid (pretomanid). The Global Alliance for TB Drug Development, New York, NY.
147 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
148 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
149 Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
150 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
151 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
152 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
153 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
154 Product Information. Lunesta (eszopiclone). Sepracor Inc, Marlborough, MA.
155 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
156 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
157 Cerner Multum, Inc. "Canadian Product Information.".
158 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
159 Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
160 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
161 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
162 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
163 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
164 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
165 Fabre C, Criddle J, Nolder D, Klein JL "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin." Trans R Soc Trop Med Hyg 99 (2005): 871-3. [PMID: 16099004]
166 Product Information. Lariam (mefloquine). Roche Laboratories, Nutley, NJ.
167 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
168 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
169 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
170 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
171 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
172 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
173 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
174 Product Information. Marqibo (vinCRIStine liposome). Talon Therapeutics Inc, South San Francisco,, CA.
175 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
176 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
177 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
178 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
179 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
180 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
181 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
182 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
183 Product Information. Targretin (bexarotene) Ligand Pharmaceuticals, San Diego, CA.
184 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
185 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
186 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
187 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
188 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
189 MHRA. Medicines and Healthcare Products Regulatory Agency "Orlistat: theoretical interaction with antiretroviral HIV medicines.".
190 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
191 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
192 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
193 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
194 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
195 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
196 Product Information. Aczone (dapsone topical). QLT USA, Inc, Fort Collins, CO.
197 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
198 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
199 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
200 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
201 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
202 Product Information. Nexavar (sorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
203 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
204 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
205 Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A "The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers." Br J Clin Pharmacol 49(suppl 1) (2000): s65-70. [PMID: 10771457]
206 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
207 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
208 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
209 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
210 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
211 Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
212 Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
213 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
214 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
215 Product Information. Cordarone (amiodarone). Wyeth-Ayerst Laboratories, Philadelphia, PA.